Epratuzumab seen as well-tolerated, steroid-sparing treatment for lupus
Source: Healio Rheumatology
Newly published results by S.L.E. Lupus Foundation Board member Dr. Daniel Wallace found that treatment of moderate to severe systemic lupus erythematosus with epratuzumab infusions was well tolerated and associated with sustained improvements in disease activity and health-related quality of life. The treatment was also associated with reduced steroid use, according to an analysis of data from an open-label extension trial.
Patients with systemic lupus erythematosus who completed a randomized controlled trial and received epratuzumab at one of five doses were invited to participate in an open-label extension trial receiving treatment with 1,200-mg epratuzumab plus standard of care. Of the 203 patients who participated, 113 patients completed the treatment protocol. Overall, 90 patients withdrew from the study, including 23 due to lack of efficacy and seven due to pregnancy. One death occurred and was not considered to be related to treatment.
Dr. Wallace concluded that open-label epratuzumab treatment was well tolerated for up to 3.2 years, and associated with sustained improvements in disease activity and quality of life, while steroids were reduced.